Host Defense Turned Viral Offense; Engineering the Next Generation of Oncolytic Adenoviruses
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
prostate cancer (oncolytic adenovirus + RNAi gene therapy)
Modality
Gene Therapy
Mechanism
oncolytic adenovirus with shRNA (CRAd strategy)
Target
PSMA
rNPV Envelope
Low
-$57.6M
costs +25% · peak −25%
Base
-$44.7M
cumulative PoS 1.7%
High
-$31.8M
costs −25% · peak +25%
The profile is an illustrative oncolytic adenovirus prostate envelope. PoS is below a modern viral-immunotherapy candidate because the asset is old, preclinical, and not a named clinical product despite active patent coverage into 2030.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #43 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#38) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
p21/Waf-1 shRNA-armed prostate CRAd
The direct JHU asset: a prostate-specific conditionally replicating adenovirus armed with shRNA against p21/Waf-1 to increase androgen-receptor promoter activity and viral potency.
Criteria 1 and 2: exact mechanism and indication; preclinical platform/candidate hybrid.
CAN-2409 / ProstAtak
Closest contemporary prostate adenoviral clinical archetype. It is replication-defective HSV-tk/prodrug immunotherapy, not CRAd plus shRNA, so it anchors development path rather than mechanism.
Criteria 2 and 4: same organ and viral platform family; adjacent clinical archetype.
Oncorine / H101
Approved oncolytic adenovirus precedent that sets the ceiling for claiming adenoviral-virotherapy regulatory validation.
Criteria 3 and 4: oncolytic adenovirus regulatory archetype; different cancer and vector design.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $18.0M | 24 mo | 36.0% | [0] [1] |
| Phase I | $60.0M | 18 mo | 56.0% | [1] [2] |
| Phase II | $130.0M | 30 mo | 24.0% | [1] [2] [3] |
| Phase III | $260.0M | 42 mo | 43.0% | [2] [3] |
| NDA/BLA Review | $16.0M | 12 mo | 84.0% | [3] |
Multiplier handling: Eligible multipliers (targeted_delivery_rationale) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$220.0M peak · WACC 15.0%
Peak revenue. A realistic academic value path is partnering the CRAd/shRNA construct into a viral-immunotherapy developer. The illustrative peak is held at $220M because prostate cancer standards are crowded and no clinical candidate has been established.
WACC. Old preclinical oncolytic adenovirus/shRNA risk plus competitive prostate standards warrants a high discount rate.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$44.7M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$153.0M
P25
-$56.2M
P50 (median)
-$19.3M
P75
-$11.4M
P95
-$6.1M
Prob ≥ 0
0.7%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is a p21/Waf-1 shRNA-armed prostate CRAd cmo_findings.asset_class_reality | Host Defense Turned Viral Offense; Engineering the Next Generation of Oncolytic Adenoviruses regulatory | 2014-10-07 | high |
Primary shRNA-armed CRAd publication stage_profile.preclinical.pos | Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses peer_review | 2010-08-01 | high |
Prostate adenoviral clinical archetype comparators[1] | Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer trial_disclosure | 2025-01-01 | high |
Approved oncolytic adenovirus archetype comparators[2] | Oncorine, the World First Oncolytic Virus Medicine and its Update in China peer_review | 2017-11-01 | high |
Thesis
Why this asset earns its rank
This is a preclinical oncolytic adenovirus/shRNA construct, not a generic gene-therapy asset. The JHU technology arms a prostate-specific CRAd with p21/Waf-1 shRNA to increase androgen-receptor promoter activity and viral potency. The pinned gene_therapy bucket is left unchanged, but the modality reality is oncolytic adenovirus plus RNAi. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified partnership_candidate rather than vc_fundable.
The comparator set is adjacent and cautionary. CAN-2409 anchors prostate adenoviral clinical development, while Oncorine anchors the limited global approval precedent for adenoviruses; neither proves this old CRAd/shRNA design can compete in modern prostate cancer. The engine result is -$57.6M to -$31.8M, with a base rNPV of -$44.7M and cumulative PoS of 1.7%; it supports a partner-first read, not a standalone company formation case.
Verdict: more product-like than a pure tool, but still a platform/candidate hybrid needing a viral-therapy sponsor. It earns its rank from prostate relevance and gene-therapy scoring, while the CMO reality is that old oncolytic adenovirus designs require decisive modern differentiation.
Key risks
Asset-specific, not generic biotech risks
- Modality mismatch: the true modality is oncolytic adenovirus plus shRNA, not a conventional gene replacement therapy.
- Old-platform risk: the primary publication is from 2010 and no clinical program appears to have advanced from this construct.
- Prostate competition: modern prostate cancer care includes AR-axis therapies, radioligands, PARP inhibitors, radiation, and localized-care standards that make viral add-on positioning hard.
- Delivery risk: intraprostatic or systemic adenovirus administration must overcome immunity, biodistribution, and local inflammation.